Search

Purpose: To demonstrate changes in three-dimensional choroidal volume with enhanced depth imaging optical coherence tomography (EDI-OCT) in patients with recurrent stage of Vogt-Koyanagi-Harada dis...

Purpose: To report the manifestation of Vogt–Koyanagi–Harada-like disease (VKH) following yellow fever vaccination.Methods: Case report.Results: A 34-year-old immunocompetent male had tinnitus, hea...

Introduction: Vogt-Koyanagi-Harada (VKH) is an autoimmune disorder affecting melanocyte-containing tissues. Major histocompatibility complex, class II, DR beta1 (HLA-DRB1)*04 and its suballele HLA-DRB1*0405 were found to be associated with VKH in many studies.Purpose: To determine the association of HLA-DRB1*04 and its suballele HLADRB1*0405 with VKH patients of Malay descent.Materials and methods: A case control study was conducted among VKH patients of Malay ethnicity attending Ophthalmology Clinic, Hospital Selayang, Malaysia from December 2016 to December 2017. HLA-DRB1*04 allele-specific typing was performed on 14 Malay patients with VKH and 14 healthy controls using the polymerase chain reaction sequence-specific primer method. The data was then analysed using Fisher’s Exact test.Results: The frequency of HLA-DRB1*04 was noted to be higher in patients (42.9%) compared to controls (14.3%), but was not statistically significant (p = 0.209). The frequency of suballele HLA-DRB1*0405 was also increased in patients (42.9%) vscontrols (7.1%); however, the results were not significant (p = 0.077).Conclusion: In conclusion, although the findings were not statistically significant, the increased frequency of both HLA-DRB1*04 and its suballele HLA-DRB1*0405 may suggest a possible cause for the development of VKH among Malay patients.

To describe disease characteristics and outcomes of Vogt-Koyanagi-Harada (VKH) syndrome in paediatric patients.Retrospective chart analysis.Analysis of all patients ≤16 years with VKH syndrome was done. Clinical presentations, complications, recurrences and outcomes in cases of paediatric VKH were reviewed.72 eyes of 36 patients with a mean age at presentation of 13.7 ± 2.34 years were assessed. Mean duration of symptoms and follow up were 9.88 ± 17.3 weeks and 55 months respectively. Clinical signs at presentation included anterior chamber cells2+(34/72eyes, 47.2%), granulomatous keratic precipitates (6 eyes, 8.3%), posterior synechiae (35 eyes,48.6%), disc edema (46 eyes, 63.8%), neurosensory retinal detachments (44 eyes, 61.1%) and 'sunset-glow' fundus (9 eyes, 12.5%). Best corrected visual acuity (BCVA) at the time of presentation was 1.3logMAR or a Snellens equivalent of 20/400 which improved to 0.51logMAR (Snellens equivalent of 20/63) at last follow up. Remission was achieved in 61.1% cases. More than half of our patients developed one or more complications.VKH in paediatric patients poses a challenge due to a delayed presentation and paediatric VKH patients have a worse visual acuity at the time of presentation as compared to adult age groups. Rates of remission may be low along with high risk of complications and hence there is a need for prolonged immunosuppression.

PURPOSE to report optical coherence tomography (OCT) changes of the retina during acute and recovery phases in a patient with atypical Vogt-Koyanagi-Harada (VKH) disease presented for the first time with ocular symptoms and role of (OCT) in the diagnosis, following and assessing response to treatment.Methods Ophthalmologic examination, laboratory evaluation, fluorescein angiography, and spectral-domain optical coherence tomography performed on a twenty-four-year-old female presented with a bilateral blurring of vision of 3 days.ResultsOCT disclosed multifocal subretinal lobulated cystic fluid collections with thickening and hyper-reflectance in outer retinal layers. Decreased retinal thickness and resolving subretinal fluid collections were seen after commencing treatment by systemic corticosteroids. Conclusion OCT is a very sensitive tool to diagnose and monitor the highly detailed retinal changes during the VKH course especially if presented primarily with ocular symptoms

The authors have requested that this preprint be removed from Research Square.

To evaluate the efficacy of Rituximab (RTX) therapy in patients affected by Vogt-Koyanagi-Harada (VKH) disease poorly controlled by traditional immunosuppressive treatment.Retrospective case series of recurrent VKH uveitis treated with intravenous RTX between January 2019 and November 2020. All patients were treated with intravenous RTX and underwent complete ophthalmic examination, best-corrected visual acuity (BCVA), fundus photography, subfoveal choroidal thickness (SFCT) measurement on enhanced depth imaging optical-coherence tomography (EDI-OCT), fluorescein, and indocyanine green angiography.Five patients were included. All patients received at least 3 RTX infusions. Mean BCVA improved from 20/32 Snellen equivalent at baseline before RTX treatment to 20/28 Snellen equivalent (In these case series, RTX was effective in VHK disease poorly controlled by traditional immunosuppressive treatment.

This is a Photo Essay and does not have an abstract. Please download the PDF or view the article in HTML.

Purpose: It is crucial to subdivide Vogt–Koyanagi–Harada (VKH) disease into two subentities, initial-onset disease versus chronically evolving disease. For early diagnosis and precise follow-up of VKH choroiditis, the “Revised criteria for VKH” are no more sufficient for the appraisal of VKH and new biomarkers for disease activity are needed. It has been shown that, if initial-onset disease is treated promptly within the “therapeutic window of opportunity” and long enough with dual steroidal and non-steroidal immunosuppression, the disease can be cured in a large proportion of cases, an approach still contested. The proportion of chronic evolution and/or sunset-glow fundus (SGF) following steroidal monotherapy versus dual steroidal and non-steroidal immunosuppression was compared. Methods: A literature search was performed, identifying studies on initial-onset VKH treated either by steroidal monotherapy or dual immunosuppression. Evolution toward chronicity and/or SGF was compared in both groups. Results: Twenty studies were identified with reported long-term outcomes. In 16 studies, 802 patients received steroidal monotherapy, while in 4 studies, 172 patients received dual steroidal and non-steroidal immunosuppression. Chronic evolution and SGF occurred, respectively, in 44% and 59% in the corticosteroid-alone group versus 2.3% and 17.5% in the dual therapy group with no chronic evolution in three studies and no SGF in two studies. Conclusions: Chronic evolution and SGF are significantly less frequent in initial-onset VKH when treated with immediate dual steroidal and non-steroidal immunosuppression with a high proportion of healed cases. This combined approach seems recommended in the management of initial-onset VKH disease.

Vogt-Koyanagi-Harada syndrome(VKH) is a multisystemic disorder characterized by granulomatous panuveitis and cutaneous, otorhynolaryngologic and neurologic involvement, due to an autoimmune reaction against melanocytic antigens. Autoinflammatory associations of VKH, including inflammatory bowel disease and psoriasis, were rarely described. SAPHO syndrome (an acronym for synovitis, acne, hyperostosis, pustulosis and osteitis) is a rare autoinflammatorymusculo-scheletal disease. This paper reports on a male patient presenting for long-lasting bone and joint pain, dysphagia,having a ten-year history of bilateral optic neuritiswhich required high-dose corticosteroids. Fundoscopy revealed diffuse chorioretinalnonpigmented atrophic lesions. Vitiligo, acne scars, clavicular deformity, recurrent chest pain and sacroiliitis pointed to a long-standing SAPHO syndrome and late-phase VKH. Blood tests found inflammation and anti-hepatitis C antibodies with repeatedly undetectable viremia. Bone scintigraphy with the characteristic bull�s head upper chest uptake and the radiographs confirmed SAPHO syndrome. The patient was treated with sulphasalazine and cyclosporin A, with alleviation of the articular and bony disease. In conclusion, SAPHO syndrome may add to the list of the diseases associated with VKH. Although VKH and SAPHO syndrome may have appeared coincidentally, a common pathogenesis involving an infectious trigger and IL-17 could be considered.

OBJECTIVES To measure the serum level of IL-33 in patients with Vogt-Koyanagi-Harada disease (VKH) and Behcet's uveitis (BU) in the Chinese Han population and investigate its associations with disease activity and clinical parameters. METHODS Serum was collected from 41 VKH patients (16 active and 25 inactive patients), 60 BU patients (24 active and 36 inactive patients), and 36 healthy controls. The serum level of IL-33 was measured using the enzyme-linked immunosorbent assay (ELISA) method. Demographic features, clinical manifestations, and intraocular inflammation activity scores (anterior chamber cells score, anterior chamber flare score, and vitreal haze score) were recorded. RESULTS The serum level of IL-33 significantly increased in all VKH patients, active VKH patients, and inactive VKH patients, as compared to healthy controls (p < 0.001, p < 0.001, and p = 0.002, respectively), and was higher in the active VKH than in the inactive VKH patients (p = 0.049). The serum level of IL-33 positively correlated with the anterior chamber cells score, vitreal haze score, and the annualized number of relapses in VKH patients (Rho = 0.359, p = 0.021; Rho = 0.344, p = 0.028; Rho = 0.537, p < 0.001, respectively). Serum IL-33 level was significantly associated with the annualized number of relapses in patients with BU (Rho = 0.361, p = 0.005). CONCLUSION Serum IL-33 level is significantly increased in VKH patients in the Chinese Han population. IL-33 level is in positive correlation with the activity and relapses of VKH. Increased IL-33 might contribute to the pathogenesis of VKH and serve as a potential biomarker for VKH disease.

Purpose: To evaluate retinal and choroidal microvascular features of VKH patients in acute and convalescent phases after treatment using OCTA. Methods: A prospective, observational study was conducted in patients with initial VKH at the acute stage (n = 15) and healthy participants (n = 15) served as controls. After 3-month systemic corticosteroid treatment, patients’ vascular parameters were recorded by OCTA before and after treatment and compared with results observed in healthy participants. Results: Our findings first uncovered that there are two types of abnormalities in the choriocapillary layer of patients with VKH in the acute stage: one is characterized as multiple dark spots of choriocapillary flow void and the other involves highly reflective areas surrounded by light spots with an increased flow area. During the convalescent stage, all eyes showed multifocal dark spots in the choriocapillary layer, leading to a reduced choroidal flow area. Conclusions: OCTA provides a better display of the microvascular appearance of the choroid to noninvasively evaluate choriocapillaris abnormalities in VKH disease.

Purpose: To report on ocular Vogt–Koyanagi–Harada (VKH)-like syndrome under vemurafenib treatment for metastatic melanoma.Design: A case report.Method: Description of clinical and imaging manifesta...

Purpose-To report a rare presentation of Vogt-Koyanagi-Harada (VKH) disease in a 55 year old female patient with unilateral limbal stem cell deficiency (LSCD) with corneal perforation. Observations-Patient presented to the out patient department with recurrent episodes of watering, pain, redness in the left eye. Examination revealed LSCD with areas of pannus and infiltration. She was treated medically. Patient came back after a year with a corneal perforation in her left eye. The perforation was sealed using cyanoacrylate glue. Six weeks later, she presented with a drop in vision in both eyes. Optical Coherence Tomography (OCT) in both eyes showed multiple sub retinal fluid pockets and Fundus Fluorescein Angiography (FFA) revealed multiple pinpoint leakages typical of Harada disease. The patient was investigated for systemic associations, which were found to be normal. She was managed with tapering doses of oral steroids. OCT showed resolution of fluid pockets at one month. There was a good control of the disease, with no signs of recurrence at 6 months follow up. Conclusion-The clinical association between the two entities has not been published in literature till date. Further data or reports on such cases would help throw light on any possible association between LSCD and VKH disease.

Purpose: Leukemias can involve almost every part of the human eye. Ophthalmic manifestations of leukemias can be divided into direct infiltration, secondary vascular changes and neuro-ophthalmological changes. Our case presented with exudative retinal detachment mimicking Vogt Koyanagi Harada's disease (VKH). Observations: A 30-years old Asian (Indian) female presented with insidious onset of painless diminution of vision from her right eye for one month. She gave history of fever and severe headache at the time of onset of ocular symptoms. Fundus examination revealed exudative retinal detachment at the posterior pole of her right eye. Fundus fluorescein angiography showed early stippled pin point hyperfluorescence, placoid pooling of the dye and late disc staining in both the eyes. A provisional diagnosis of Vogt Koyanagi Harada disease was made and routine blood investigations and a physician check-up for fitness for systemic steroids was done. Peripheral blood smear showed the presence of blast cells. The patient was diagnosed to have Acute Myeloid Leukemia (AML) and was started on chemotherapy. Conclusions and Importance: Acute myeloid leukemia can present as an exudative retinal detachment and can mimic similarly presenting conditions like VKH. Hence, this very important differential diagnosis should be kept in mind and it stresses the importance of simple laboratory investigations like whole and differential blood counts.

Vogt–Koyanagi–Harada disease is rare granulomatous inflammatory disease that affects pigmented structures, such as choroid, inner ear, meninges, hair, and skin. Ocular involvement is characterized by bilateral, diffuse, granulomatous panuveitis and exudative retinal detachment. Vogt–Koyanagi–Harada disease has usually a benign course if diagnosed early and adequately treated. Imaging remains an integral part of diagnosis of Vogt–Koyanagi–Harada disease and plays an important role in diagnosis, quantification of inflammation, and disease monitorization.

We report our experience in B-mode ocular ultrasonography, focusing on its contribution when the clinical examination proves to be difficult, mainly due to the existence of intraocular opacities of the ocular fundus or diagnostic doubts. We revise the ocular ultrasound technique, its indications and contraindications, comparing to the other imaging techniques. In our experience ultrasonography revealed pathological findings which confirmed the clinical suspicion in most of cases or provide additional information. With understanding of the indications for ultrasonography and proper examination technique, one can gather a vast amount of information not possible with clinical examination alone.Riportiamo la nostra esperienza di ecografia oculare in B-mode, concentrandoci sul suo contributo quando l’esame clinico si riveli difficile, principalmente per l’esistenza di opacità intraoculari del fondo o in presenza di dubbi diagnostici. Rivediamo la tecnica ecografica, le sue indicazioni e controindicazioni, anche a confronto con le altre tecniche di imaging. Nella nostra esperienza l’ecografia ha rilevato reperti patologici che, nella maggior parte dei casi, hanno confermato il sospetto clinico, o fornito informazioni aggiuntive. Limitando le indicazioni ed eseguendo l’esame con tecnica corretta, si possono raccogliere una grande quantità d’informazioni che non è possibile avere con il solo esame clinico.

Vogt Koyanagi Harada (VKH) Syndrome, also called uveomeningioencephalitis, is a chronic disorder characterized by inflammation of the uvea, meninges, auditory system, and integumentary system. The association between VKH syndrome and multiple sclerosis (MS) has been reported only once in the literature in a patient who developed VKH syndrome after two years of the diagnosis of MS. In this article, we report a case who was misdiagnosed and treated as MS until she was proven to have VKH syndrome, and a diagnosis of MS was excluded. VKH syndrome is a systemic disorder that may present with clinical and/or radiological features mimicking MS. Applying diagnostic criteria is extremely important for confirming or excluding the diagnosis. Detailed history and physical examination are of paramount importance to score the final diagnosis. Rigorous search for red flags for both conditions is very helpful.

Purpose: To compare enhanced depth imaging (EDI-OCT) and swept source optical coherence tomography (SS-OCT) in assessment of Vogt–Koyanagi–Harada (VKH) disease.Methods: All consecutive VKH patients seen at Singapore National Eye Centre during 2012–2013 were imaged using both modalities. Subfoveal choroidal thickness (SFCT) was measured by one masked trained observer.Results: A total of 137 pairs of scans were obtained from 48 patients. SFCT was more likely to be measurable on SS-OCT than EDI-OCT (112, 81.8%; 84, 61.3%; p

Vogt–Koyanagi–Harada syndrome is an autoimmune multisystem disease, characterized by the association of ocular inflammatory manifestations (uveitis and retinal detachment) and extraocular lesions such as meningismus and tegumentary or auditory findings. We report the case of a Hispanic woman with this syndrome.

Vogt-Koyanagi-Harada (VKH) disease is a chronic, bilateral, granulomatous panuveitis associated with cutaneous, neurologic, and auditory manifestations. We report a 4-year-old Saudi boy who developed severe ocular complications by 5 years of age. He presented to King Khalid Eye Specialist Hospital at the age of 4 years and was previously operated on elsewhere for cataract with intraocular lens implantation in his right eye at the age of 3 years. He consecutively had iris capture and membrane formation around the intraocular lens. Examination revealed band keratopathy, posterior synechiae, and fundus depigmentation in both eyes with cataract formation in his left eye. At the age of 5.5 years, he developed subretinal neovascular membrane formation in the left eye. To the best of our knowledge, this patient is youngest VKH case that manifested most of the major complications at a young age as 5 years old.

Resume Les effets immunologiques complexes de la bitherapie associant interferon et ribavirine au cours du traitement de l’hepatite C peuvent aggraver ou declencher une reaction auto-immunitaire. Nous rapportons un cas rare de maladie de Vogt-Koyanagi-Harada survenue chez un patient suivi pour une hepatite C chronique apres institution d’un traitement associant de l’interferon-alpha2a et de la ribavirine. Le role potentiel de l’interferon-alpha et/ou de la ribavirine est discute, en insistant sur l’association entre le traitement de l’hepatite C par interferon-alpha/ribavirine et le developpement de la maladie de Vogt-Koyanagi-Harada. Une telle complication ophtalmologique grave exige un suivi ophtalmologique etroit de tous les patients ayant une hepatite C traitee par interferon-alpha.

Resume Propos Le syndrome de Vogt-Koyanagi-Harada est une affection systemique, rare, caracterisee par l'association de plusieurs symptomes : oculaires, meninges, auditifs et cutanes ; celle-ci se manifeste plus souvent dans les races pigmentees ; sur le plan physiopathologique, il s'agit d'une auto-immunisation ou le melanocyte serait la cellule cible. Methodes Le but de ce travail retrospectif est de determiner les caracteristiques cliniques, therapeutiques et evolutives des patients atteints de cette affection, sous nos climats. Resultats Huit cas ont ete colliges sur une periode de 22 ans : tous les malades repondaient aux criteres revises de l'American Uveitis Society. Tous les patients etaient de sexe feminin. L'atteinte oculaire, bilaterale dans tous les cas, se presentait surtout sous forme d'une panuveite chez les huit patients. Le decollement retinien etait observe chez quatre patients. L'atteinte meningee etait retrouvee dans six cas. Sept patients presentaient une dysacousie et cinq avaient une atteinte cutanee representee essentiellement par la poliose. Sur le plan therapeutique, tous les patients ont recu une corticotherapie generale et/ou immunosuppresseurs, entrainant une amelioration chez cinq patients. Conclusion Nos donnees confirment le pronostic visuel en general favorable. Les immunosuppresseurs pourraient etre utilises precocement en cas d'atteinte oculaire posterieure.

Rituximab was trialed in a refractory Vogt-Koyanagi-Harada disease (VKH). A 10-year-old girl with panuveitis recalcitrant to treatment, including corticosteroids, was diagnosed with VKH 20 months later. Following rituximab at 0, 1, 6, and 18 months, response was favorable after the second dose, usual life activity resumed after the third dose (uveitis was inactivated and vision improved), and eyes stabilized 9 months after the fourth dose. Rituximab is effective in the treatment and long-term control of advanced, pediatric VKH.

To report on the use of immunomodulatory therapy (IMT) in a group of patients with Vogt-Koyanagi-Harada disease (VKH) and to compare the outcomes with those of another group of patients with VKH who were treated for prolonged periods with corticosteroids.Treatment regimens and their respective outcomes (visual acuity) were compared for the following groups: prolonged steroid with or without delayed addition of IMT (Group 1) and relatively prompt IMT with or without steroid (Group 2).The average duration of follow-up in Group 1 was 28.9 months and in Group 2 23.4 months. In Group 1, visual acuity deteriorated in three of the five patients (60%) and improved in one (20%). The fifth patient showed improvement in visual acuity in one eye, but decreased visual acuity in the other eye. In Group 2, seven of the eight patients showed improvement in their visual acuities (87.5%); visual acuity deteriorated in one patient (12.5%).The results suggest that IMT as first-line therapy for VKH is associated with a superior visual outcome when compared to steroid as monotherapy or with delayed addition of IMT.

Purpose To present a case of Vogt-Koyanagi-Harada (VKH) associated with type I diabetes mellitus and celiac disease in a 3 year old female. Methods We studied a three-year old female who presented with clinical manifestation of VKH and type I Diabetes mellitus and ciliac disease. Results Patient was found to have hyperglycemia with type I diabetes mellitus. Duodenal mucosal biopsy specimen confirmed the diagnosis of celiac disease. Patient's ocular inflammation was treated by topical and systemic corticosteroid and immune-suppressive therapy. Her diabetes mellitus was controlled by insulin and her celiac disease was controlled by gluten-free diet. Conclusions The association of VKH with two autoimmune diseases (celiac disease and type I diabetes mellitus) is rare. This case is, to our knowledge, the youngest patient reported with VKH.

Vogt-Koyanagi-Harada (VKH) disease presents with anterior segment inflammation, choroiditis and exudative retinal detachment. Following resolution of the inflammation, VKH patients have been noted to complain of visual disturbances despite good visual acuity. We therefore investigated the visual function deficits of convalescent VKH patients.A cross-sectional observational nonrandomized controlled study of convalescent VKH patients from the Uveitis Service of the Singapore National Eye Centre, and normal subjects was performed. The best-corrected visual acuities (BCVA) and multifocal electroretinograms (mfERGs) of VKH patients with and without peripapillary atrophy (PPA) were compared with those of the normal eyes. The mfERG results were subdivided into those obtained from the peripapillary area and those from the rest of the macular.Eleven VKH eyes with large PPA to disc ratios (PPA/D ratio2), 15 VKH eyes with PPA/D ratios1 and 6 normal eyes were included in the study. Five eyes (54.5%) of VKH patients with PPA/D2 had a BCVA of less than 20/40. All the other eyes had 20/20 vision. Nine of the 11 VKH eyes with PPA/D2 also had large areas of chorioretinal atrophy. The mfERG responses of VKH eyes with PPA/D ratio2 were markedly reduced in amplitude (p0.001) and delayed in implicit time (p0.001) throughout the entire macular area. VKH patients with PPA/D ratio1 had significantly reduced mfERG amplitudes throughout the entire macular area, as well as delayed implicit times at the peripapillary region (p=0.026). Sub-division of VKH eyes with PPA/D1 into eyes with no PPA and eyes with a small PPA, showed that both groups had a similar reduction in response amplitude over the entire macular region. However, the implicit time was significantly delayed in eyes with small PPA when compared to those without PPA (p0.03).VKH patients with large PPA have clinically significant visual dysfunction. VKH patients without PPA also have subclinical retinal dysfunction. The mfERG may be a useful adjunct in the management of VKH by detecting early retinal damage.

Introduction Nous avons etudie 17 cas consecutifs de syndrome de Vogt-Koyanagi-Harada, ayant consulte dans le service d’ophtalmologie entre 1997 et 2002, afin d’en determiner le profil clinique. Materiel et methodes Il s’agit d’une etude monocentrique retrospective descriptive de 17 cas de syndrome de Vogt-Koyanagi-Harada. Resultats Le sex-ratio etait de 1,6 avec 11 femmes (65 %) pour 6 hommes (35 %). L’âge moyen etait de 37,65 ± 10,2 ans. La serie comportait 7 patients d’Afrique du nord (41 %), 8 Caucasiens (47 %) et 2 d’Afrique noire (12 %). Onze patients ont ete vus initialement a la phase aigue, tandis que 6 patients ont ete vus secondairement. La panuveite avec decollement sereux retiniens etait la presentation la plus frequente (88 %). Tous les patients presentaient une atteinte bilaterale. Les signes extraoculaires etaient retrouves chez 87 % des patients. L’acuite visuelle moyenne initiale etait de 0,29 ± 0,36 et l’acuite visuelle finale etait de 0,78 ± 0,3. Tous les patients vus a la phase aigue ont ete traites par corticotherapie generale. Un traitement immunosuppresseur a ete necessaire dans 56 % des cas. Conclusions Le syndrome de Vogt-Koyanagi-Harada, dans une population caucasienne et africaine, a une presentation ophtalmologique et extraophtalmologique proche de celle de la population japonaise. En revanche, les signes cutanes sont beaucoup plus rares. Le pronostic visuel est globalement favorable.

Objective: To compare enhanced depth imaging optical coherence tomography (EDI-OCT) and swept source OCT (SS-OCT) images in Vogt-Koyanagi-Harada (VKH) disease to determine the agreement of subfoveal choroidal thickness (SFCT) measurements between them. Methods: SFCT of one eye of all consecutive VKH patients seen at the Singapore National Eye Centre during 2012 to 2013 was measured using both modalities by one masked trained observer. Charts were retrospectively reviewed for demographics, duration of disease and phase of disease. The acute phase was defined as being within the first 6 months of onset and the chronic phase any time thereafter. Results: 137 SS-OCT and EDI-OCT scans were obtained from 48 patients. Mean age was 52 years. Majority were Chinese (31 patients, 65%) and females (29,60%). The quality of SS-OCT images were superior to EDI-OCT during the acute phase but were similar in the chronic phase. There was good inter-OCT correlation for both the acute and the chronic phase (Mean difference in SFCT ± 2 standard deviation of -22.7 ± 39.4 microns and -13.0 ± 42 microns respectively).The mean SFCT was greater the in acute phase (352.4 microns, SD 89.5) than in the chronic phase (221.5 microns, SD116.1, P

Le syndrome de Vogt-Koyanagi-Harada (VKH) est une affection systémique rare, sévère mettant en jeu le pronostic visuel malgré les traitements agressifs, caractérisée par l'association de plusieurs symptômes: oculaires, méningés, auditifs et cutanés secondaire à une auto-immunisation où le mélanocyte serait la cellule cible. Nous rapportons un nouveau cas rare où l'atteinte oculaire est isolée. La sévérité de l'uvéite réside dans la fréquence des récidives, dans la cortico-résistance et dans la forte incidence des complications qui conditionnent le pronostic et expliquent les acuités visuelles finales médiocres. La prise en charge doit être précoce afin d'essayer d'améliorer le pronostic visuel.Key words: Vogt Koyanagi Harada, décollements séreux rétiniens, pin-points, uvéite